INCY News and Press, Incyte Corporation From 05/03/22

Incyte's (NASDAQ:INCY) Q1 2022 net income fell ~17% year over year to ~$122.9M on a non-GAAP basis as the biotech was hampered in the quarter by significant increases in operating expenses. Revenue of $733.24M was a ~21.3% year over year increase but still missed Street estimates. Sales of Ja...

Incyte Corporation (INCY) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Christine Chiou – Head-Investor Relations Hervé Hoppenot – Chairman, President and Chief Executive Officer Barry Flannelly – Executive Vice President and General Ma...

Incyte press release (NASDAQ:INCY): Q1 Non-GAAP EPS of $0.55 misses by $0.14. Revenue of $733.24M (+21.3% Y/Y) misses by $20.3M. The Company has reaffirmed its full year 2022 financial guidance:  Jakafi guidance range of $2.33 to $2.4 billion for 2022 (prior $2.3 - $2.4 billion). Th...

Total product and royalty revenues of $728 million in Q1’22 (+20% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $544 million in Q1’22 (+17% Y/Y); raising the bottom end of full year guidance to new range of $2.33 to $2.40 billion Robust u...

Are These The Best Biotech Stocks To Buy Right Now? In the stock market, many investors bank on the prospect of a company rather than what it currently has to offer. Biotech stocks would be a prime example for this investment approach. The industry includes companies that develo...

Incyte (NASDAQ:INCY) Q1 consensus EPS estimate is $0.69 (+3.0% Y/Y) and consensus revenue estimate is $753.54M (+24.6% Y/Y). INCY will report Q1 earnings results tomorrow, May 3, before market open. Over the last 2 years, INCY has beaten EPS estimates 63% of the time and revenu...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nasdaq stocks have come under pressure this year Incyte ( INCY ): The biopharmaceutical company expects continued revenue growth from its flagship drug Ruxolitinib after the FDA approval for additional treatm...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Incyte (NASDAQ:INCY) and Maruho on Thursday announced a deal for exclusive commercialization of ruxolitinib cream to treat autoimmune and inflammatory dermatology indications in Japan. This is a novel cream formulation of INCY's selective JAK2 inhibitor ruxolitinib. Maruho will make an upfron...

Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK2 inhibitor ru...